SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following FDA approval of BYSANTI for bipolar I disorder and schizophrenia, which the community views as a major rerating event due to its patent protection until 2044. This, combined with the perceived "mega blockbuster" potential of Tradipitant for GLP-1 induced nausea, is fueling discussions of significant undervaluation and strong buyout speculation among big pharma.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending amidst heightened buyout speculation, with French reports citing interest from Eli Lilly and AstraZeneca for its promising ulcerative colitis drug, obefazimod, further bolstered by recent data on its anti-fibrotic activity at ECCO 2026; the community is keenly debating potential acquisition valuations and comparing its trajectory to past biotech successes.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is actively trending as community members discuss its current low valuation, with many expressing long-term optimism and encouraging accumulation while highlighting its 'move-to-earn' utility where users earn crypto through physical activity and can utilize or stake their tokens for rewards.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

QQQI, the NEOS Nasdaq 100 High Income ETF, is trending due to its consistently high monthly dividend payouts, often cited around 14%, derived from its Nasdaq 100 options strategy. The community is actively discussing its appeal as a robust passive income vehicle, frequently comparing its tax-efficient distributions and perceived NAV stability against other income funds for retirement planning and varied market conditions.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is trending as a "SaaSpocalypse" narrative, driven by fears that AI models like Anthropic's Claude will disrupt and replace traditional software, has led to a significant sell-off. However, the community widely views this as an illogical overreaction, asserting that established software companies will integrate AI to enhance their strong fundamentals, rather than be displaced.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Squibb is trending due to strong quarterly results and an upbeat outlook, with community discussion focusing on how its growing portfolio of new drugs and recent regulatory milestones, including a priority review for a multiple myeloma therapy, are positioned to counter upcoming patent challenges and present a compelling value.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending amidst heated community debate regarding the Algorand Foundation's financial sustainability and perceived mismanagement, with concerns about potential token supply increases contrasting sharply against hopes for regulatory clarity and a broader altcoin market recovery.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is actively discussed after the FDA extended its review for FILSPARI in FSGS until April 2026 due to additional data; while this news caused an initial sharp drop, many in the community view the delay as a positive sign that increases the likelihood of eventual approval rather than an outright rejection for the rare kidney disease treatment.

ProShares Trust - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is trending as escalating geopolitical tensions in major oil-producing regions like Iran, Venezuela, and Russia fuel short-term bullish sentiment over potential supply disruptions. This outlook clashes with persistent market discussions about a global crude oil surplus and growing clean energy adoption, creating a deeply divided trading environment.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

The rollout of Polkadot 2.0, introducing Agile Coretime and a newly capped token supply, is driving significant conversation around the project's future and tokenomics. While supporters view these developments and recent listings as catalysts for an upcoming altcoin season, a vocal segment of the community remains highly skeptical, citing past performance and questioning its long-term utility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Comparing trending tickers $ARCT vs $AKAM:
ARCT has edged up slightly today, by 0.56% to $7.21, with trading volume at 318.6K, which is below its average of 704.8K. In contrast, AKAM has surged by 6.83% to $111.76 on a much higher volume of 7.3M shares, significantly exceeding its average of 2.7M. This shows AKAM experiencing a notable price jump accompanied by a substantial increase in trading activity, while ARCT&#39;s smaller gain comes with less trading activity relative to its usual volume.

Charles ford

StockTwits Web

Arcturus Therapeutics Holdings Inc

Akamai Technologies Inc

:
ARCT has edged up slightly today, by 0.56% to $7.21, with trading volume at 318.6K, which is below its average of 704.8K. In contrast, AKAM has surged by 6.83% to $111.76 on a much higher volume of 7.3M shares, significantly exceeding its average of 2.7M. This shows AKAM experiencing a notable price jump accompanied by a substantial increase in trading activity, while ARCT's smaller gain comes with less trading activity relative to its usual volume.